drugset / Trial / NCT00669942

Double Blind, Placebo-controlled, Study of the Safety, Tolerability and Pharmacokinetics of AIN457 in Rheumatoid Arthritis Patients

NCT00669942

Phase 1/2 Completed 104 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupDouble-blindBasic science

Summary

Evaluate the safety, tolerability and pharmacokinetics of AIN457 when administered as a single dose (intravenous infusion) in patients with active rheumatoid arthritis in combination with a stable dose of methotrexate. And to compare efficacy on the dose groups.

Timeline

Start
2005-12
Primary completion
2008-11
Completion
2008-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Secukinumab Monoclonal antibody 0.3 mg/kg Intravenous
Subject Secukinumab Monoclonal antibody 1 mg/kg Intravenous
Subject Secukinumab Monoclonal antibody 3 mg/kg Intravenous
Subject Secukinumab Monoclonal antibody 10 mg/kg Intravenous

Indications